# Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

> **NCT01479179** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** AMG 479
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01479179
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-11
- **Primary completion:** 2015-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug sponsor decision to discontinue study.
- **Last updated:** 2016-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479179, "Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01479179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*